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SUMMARY
SCHLEGEL, H. B., M. POE, AND K. HOOGSTEEN. Models for the binding of metho-
trexate to Escherichia coli dihydrofolate reductase: direct effect of carboxylate of
aspartic acid 27 upon ultraviolet spectrum of methotrexate. Mol. Pharmacol. 20:
154-158 (1981).
Ab initio molecular orbital calculations were performed on neutral and protonated 2,4-
diamino-6-methylpteridine. The computations were repeated for the N-1-protonated
molecule in a highly simplified model of the methotnexate binding site of Escherichia
coli dihydrofolate reductase. The strengths of the ionic bond to Asp 27, the hydrogen
bond to Thr 113, and the interaction with the peptide bonds between Ile 5 and Ala 6 and
between Ala 6 and Ala 7 were calculated to be 100, 10, 5, and 1 kcal/mole, respectively,
in the absence of solvent. These strengths suggest that the ionic bond is the most
important component of the binding of protonated methotrexate. The energy calculations
also provide a semiquantitative explanation of the hitherto unexplained shift to longer
wavelength of the lowest-frequency UV absorbance band of N- 1-protonated methotrexate
upon binding to dihydrofolate reductase. This shift is due to a direct effect of the
electrostatic field of the carboxylate ion of Asp 27 upon the molecular orbitals of the
methotrexate.
INTRODUCTION
The enzyme dihydrofolate reductase (5,6,7,8-tetrahy-
drofolate: NADP oxidoreductase, EC 1.5.1.3) is a drug
target of considerable therapeutic importance in cancer
chemotherapy (1). The most widely used dihydrofolate
reductase inhibitor in cancer chemotherapy is metho-
trexate, which is N-10-methyl-4-amino-4-deoxy-folic acid
(see Fig. 1). The high-resolution crystal structure of the
binary methotrexate complex of the dihydrofolate reduc-
tase from Escherichia coli has been solved by Matthews
et al (2). The E. coli reductase has a central, eight-
stranded /3-sheet as the main feature of its polypeptide
backbone, with methotrexate bound in a 15-A deep cavity
with its pteridine ring buried in a primarily hydrophobic
pocket. Matthews et al. (2) found three important fea-
tunes of the enzyme which were responsible for tight
binding of the 2,4-diaminopynimidine moiety of metho-
trexate to dihydrofolate reductase: an ionic linkage of the
carboxylate ion of Asp 27 to protonated N-i; a hydrogen
bond of the Thr 113 hydroxyl to the C-2 amino group;
and a 1T1T* interaction of the peptide bond between Ala
6 and Ala 7 and N-i, C-2 and its amino group, and N-3
(the  interaction was proposed on the basis of the
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geometry of the interaction). The features of the 2,4-
diaminopyrimidine moiety of methotrexate, i.e., N-i, C-
2 with its amino group, N-3, and C-4 with its amino
group, are found in all dihydrofolate reductase inhibitors
that are very tightly bound (3).
Our earlier calculations on dihydrofolate by the corn-
plete neglect of differential overlap, self-consistent field
method [CNDO/2; see Gund et al. (4)] have now been
extended to a series of ab initio molecular orbital calcu-
lations on a highly simplified model of the methotnexate
binding site of E. coli dihydrofolate reductase containing
2,4-diamino-6-methylpteridine in order to assess the rel-
ative importance of the various interactions. These cal-
culations correctly account for the pH dependence of the
longest-wavelength UV absorbance band of methotrex-
ate, and suggest that the ionic interaction between the
carboxylate ion of Asp 27 and N-i of protonated metho-
trexate is the most important.
When methotrexate is bound to dihydrofolate reduc-
tase, calorimetric data (5) and UV-difference spectropho-
tometnic (6-9) evidence indicate that it is protonated at
N-i when enzyme-bound. The UV difference spectrum
has three noteworthy components: (a) a component
FIG. 1 . Structure of methotrexate
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strongly resembling that observed on protonation of
methotrexate, reflecting an increased proportion of pro-
tonation on binding; (b) several narrow bands corre-
sponding to the alteration of the environment of one or
more tryptophan residues of the enzyme upon metho-
trexate binding; and (c) a shift to longer wavelength by
10-40 nrn of the longest-wavelength UV absorption band.
This latter component, hitherto unexplained, is shown in
our calculations to be attributable to a direct effect of
the electrostatic field of the carboxylate ion of Asp 27
upon the molecular orbitals of the pteridine ring.
CALCULATIONS
Our model for the methotrexate binding site in dihy-
drofolate reductase is based on the crystal structure of
the binary methotrexate complex of E. coli dihydrofolate
reductase (2). This model is given schematically in Fig.
2 and in a stereo pair in Fig. 3. These coordinates were
given to us by Drs. J. T. Bolin, D. A. Matthews, and J.
Kraut, of the University of California at San Diego. In
the model, methotrexate is represented by 2,4-diamino-
6-methyipteridine, Asp 27 by formate, Thr ii3 by water,
and the peptide bonds between Ile 5 and Ala 6 and
between Ala 6 and Ala 7 both by formamide. Each
nonhydrogen atom of the pteridine in the model is at the
same position as the corresponding atom of methotrexate















FIG. 2. Schematic model for binding site
2,4-Diamino-6-methylpteridine is numbered like the corresponding
atoms of the methotrexate. The peptide bonds between lie 5 and Ala
6 and between Ala 6 and Ala 7 are represented by formamides, the Thr
113 hydroxyl by water, and the Asp 27 carboxyl by formate. The
hydrogen atom representing the a-carbon of the Ala 6 was nearly at
the same position as the formamides representing both peptide bonds;
this is indicated by the atom in parentheses (H).
folate reductase. Similarly, the coordinates ofthe formate
are obtained from the carboxyl group on the side chain
of Asp 27. The locations of the formamide carbon, oxy-
gen, and nitrogen atoms are taken from the appropriate
atoms in the ile 5-Ala 6 and Ala 6-Ala 7 peptide bonds
in the enzyme complex. The oxygen atom of the water
modeling Thr 113 is at the same position as the hydroxyl
oxygen atom of Thr 113 in the enzyme complex, with one
0-H bond directed along the C$-O-y bond axis. The
hydrogen atoms in the model are attached with standard
bond lengths and angles’ unless otherwise noted. The 2-
amino and 4-amino groups were chosen to be planar, the
rotation of the 6-methyl group was fixed arbitrarily, and
the free hydrogen atom in the Thr 113 model was on-
ented in two different ways so that it could either accept
or donate a hydrogen bond in its interaction with the 2-
amino group.
Calculations were performed with the Gaussian 76
series of ab initio molecular orbital programs (10) using
the STO-3G basis set (ii). Isolated 2,4-diamino-6-methyl
ptenidine was computed in the neutral form and proton-
ated, in turn, at N-i, N-3, N-5, and N-8 to determine the
preferred site of protonation. The supermolecule ap-
pnoach was used to calculate the interaction energies
between the pteridine ring (both neutral and N-i proton-
ated), and each of the features of the enzyme model was
taken one at a time. No counterpoise corrections were
made, and the total interaction was approximated as the
sum of the individual interactions. Even with these sim-
plifications, only minimal basis set calculations were
practical. Such basis sets including STO-3G basis sets
have a number of shortcomings. For example, the relative
proton affinities computed for neutral nitrogen corn-
pounds and carboxylate are wrong. Hence, the position
of the hydrogen atom in the methotrexate-Asp 27 inter-
action cannot be determined from our model by geometry
optimization. Electrostatic interactions and hydrogen
bonds are predicted fairly well when minimal basis sets
are used, but polarization and charge transfer may be
underestimated. Hydrophobic effects are not handled
correctly in these calculations, since this would require
the explicit consideration of solvent entropy. With these
reservations in mind, we proceed to a cautious analysis
of our calculations.
The proton affinities for methotrexate have been cal-
culated. Although the absolute magnitudes are overesti-
mated, the relative values are reliable at the minimal
basis set level. The order of the proton affinities is N-i
(290.3 kcal/mole) > N-3 (284.4 kcal/mole) > N-8 (273.4)
> N-5 (255.8), indicating that protonation at N-i is
preferred.2 The most basic nitrogen atom of methotrex-
ate, which has a pK0 of 5.71 in water at 25#{176},has been
shown to be N-i (12).
I Standard parameters for hydrogen atoms: R(C-H) = 1.09 A except
for amide and carboxyl groups, where R(C-H) = 1.07 A and R(N-H)
= 1.00 A; for CH:, groups, where HCH = 109.5#{176}; and for NH2 groups,
where CHN = 120#{176}.Other hydrogen atoms are placed on the bisector
of the associated three-heavy-atom angle.
2 Our calculations on the relative proton affinities of 2,4-diamino-6-
methylpteridine give the same order of proton affinities as earlier
calculations by the complete neglect of differential overlap, self-con-








(: See text for details of structures.
h A negative value indicates a repulsive interaction.
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a See text for details on structures used for models.
b STO-3G optimized geometry used for water.
FIG. 3. Stereoscopic pair of the model for the binding of methotrexate to the active site of dihydrofolate reductase showing the relative
orientation of2,4-diamino-6-methylpteridine representing methotrexate, two formamides representingpeptide bonds between Ile 5-Ala 6 and
Ala 6-Ala 7, water representing the Thr 113 hydroxyl, and formate representing the Asp 27 carboxyl
The total energies for the various fragments used to
model the enzyme active site are presented in Table 1.
The interactions of these fragments with the neutral and
N-i protonated pteridine are presented in Table 2. For
neutral methotrexate, the interactions are small, as ex-
pected from the fact that methotrexate is protonated
when bound to E. coli dihydrofolate reductase (13). The
net positive charge on protonated methotrexate
strengthens each of the interactions, especially the inter-
action with Asp 27. The calculations indicate that the
carbonyl oxygen atom of the Ile 5-Ala 6 peptide bond
forms a distorted hydrogen bond with the amino group
at C-4. The peptide bond between Ala 6 and Ala 7 does
not interact strongly with the pteridine ring. Possibly
calculations with an extended basis set would enhance
this r-ir’ effect. The interaction with Asp 27 is by far the
largest and is the result of bringing two oppositely
charged molecules into close proximity. The Thr 113 can
act as either a hydrogen donor or acceptor in the bond
with the amino group at C-2. Calculations on both geo-
metries indicate that Thr 1 13 behaves as a proton accep-
tor. These interaction energies are relative to monomers
in the gas phase, since a detailed calculation of the effect
of solvent is beyond the scope of our study. Solvation of
the methotrexate and active-site models will reduce the
calculated energies substantially, with the ionic interac-
tion being affected most, perhaps by as much as one
order of magnitude. Nevertheless, the role of Asp 27 in
the binding of methotrexate should still dominate.
TABLE 1
Total energies for fragments in enzyme model




Ala 5-Ala 6 peptide bond -166.67118
Ala 6-Ala 7 peptide bond -166.68017
Asp 27 carboxyl group






Total energies of models for interaction of enzyme fragments with
neutral and N- 1 .protonated methotrexate”




Ile 5-Ala 6 bond -755.56557 -756.03179 2.4 4.7
Ala 6-Ala 7 bond -755.57139 -756.03181 -0.4 0.9
Asp 27 carboxyl -774.32397 -774.94498 0.9 100.3
Thr 113 hydroxyl -663.85759 -684.33477 0.7 9.9
The molecular orbitals obtained in the preceding cal-
culation can be interpreted to provide additional infor-
mation about the nature of the methotrexate-dihydrofol-
ate reductase interaction. The difference in the orbital
energies between the HOMO3 and the LUMO can be
related to the lowest-energy electronic transition, which
in the case of the methotrexate is a iri transition of the
pteridine ring. The orbital energy differences t#{128},herein
defined as the difference in energy between the HOMO
and LUMO, i.e., #{128}(HOMO) - #{128}(LUMO), are summarized
in Table 3. A comparison of #{128}for neutral and N-i
protonated 2,4-diamino-6-methylpteridine (#{128}= 0.4070
and & = 0.4302 atomic unit, respectively), shows that
protonation leads to an increase in i#{128},in agreement with
the shift to shorter wavelength of the lowest-energy UV
absorbance band. For the protonated pteridine plus the
Asp 27 carboxyl group, the increase in #{128}compared with
the neutral pteridine is much less. Interactions with the
other fragments of the enzyme model affect & only
slightly. The combined effect of all four components is
estimated to yield & = 0.4i45 atomic unit.
Several additional computations have been performed
to assess the influence of solvent water molecules. The
largest effect relevant to our calculations would occur
when water is hydrogen-bonded to N-i, since this is the
site where interactions with the enzyme has its greatest
.‘ The abbreviations used are: HOMO, highest occupied molecular
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N-1-H 2,4-diamino-6-methylpteri- Aco 0.4302
dine (MTX 1)
MTX 1 plus lie 5-Ala 6 peptide #{128}, 0.4306
bond
MTX 1 plus Ala 6-Ala 7 peptide &2 0.4294
bond
MTX 1 plus sp 27 carboxyl group L#{128}: 0.4162
MTX 1 plus Thr 113 hydroxyl group t#{128} 0.4289
MTX 1 plus all four enzyme frag- i#{128} 0.4145
ments”
a Total effect of interaction with enzyme fragments estimated as the
sum of the individual interactions: & - & = [#{128},- &#{176}]+ [Ac2 -
&o] + [i#{128},- i#{128}O] + [#{128} &O], where #{128}ois the HOMO-LUMO energy
difference for the protonated methotrexate model in the absence of any
interactions.
effect. However, a water molecule appropriately placed
near N-i has little effect on & of either the protonated
or unprotonated ptenidines (A#{128}= 0.4302 and & = 0.4080
atomic unit, respectively). In summary, the calculations
indicate that the shift in the wavelength of the lowest
UV band should be less for enzyme-bound, protonated
pteridines than for the protonated pteridine in solution.
DISCUSSION
The ab initio quantum chemical calculations on 2,4-
diamino-6-methylptenidine summarized here should be
directly applicable to the 2,4-diaminopteridine portion of
rnethothrexate, because the 2,4-diaminoptenidine is elec-
trically insulated from the p-aminobenzoyl-L-glutamate
moiety of methotrexate by a saturated carbon “spacer,”
which would make the electronic properties of the 2,4-
diaminopteridine independent of the rest of the molecule
[see Gund et al. (4) for an analogous calculation]. Our
model for the portions of dihydrofolate reductase that we
believe are most important in binding the 2,4-diamino-
pteridine moiety of methotrexate also involves portions
of the enzyme that are separated from the rest of the
enzyme by saturated carbon spacers, although these sat-
urated carbon atoms are replaced by hydrogen atoms for
our calculations. The replacement of the remainder of
the 2,4-diaminopteridine binding site in dihydnofolate
reductase by vacuum probably is not too bad an approx-
imation for the effects of the rest of the site, since the
interior of the enzyme is a nonpolar or low dielectric
medium; the rest of the site is also more remote from the
2,4-diaminopyrimidine portion of the methotnexate bind-
ing site.
Our calculations of the strengths of interactions be-
tween dihydrofolate reductase and methotrexate, sum-
marized in Table 3, indicate that the ionic interaction
between the carboxylate of Asp 27 and protonated N-i is
by far the most important. This result is at variance with
the conclusion of Hood and Roberts (9), who have as-
serted that only one-third of the difference in binding
FIG. 4. The HOMOs and LUMOs of N-1-protonated 2,4-diamino-
6-met hylpteridine
Solid and dashed 3-dimensional contours are drawn for orbital
amplitudes of ±0.05 electron.
energy between folate and methotrexate to Lactobacillus
casei dihydrofolate reductase arises from the difference
in charge state. Hood and Roberts (9) measured the
association constants for folate, neutral methotrexate,
and protonated methotrexate to L. casei dihydrofolate
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FIG. 5. Comparison of calculated orbital energy differences and
observed UV spectrum maxima
., Neutral methotrexate in solution (12); 0, N-1-protonated meth-
otrexate in solution (12); L, N-1-protonated methotrexate bound to
Escherichia coli dihydrofolate reductase (6).
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M’, and 2.75 x 10’#{176}M’ at pH 7.5, respectively. They
asserted that the relative values of these association
constants means that only one-third of the difference in
binding to dihydrofolate reductase between folic acid and
methotrexate, which is mostly protonated when bound,
arises from the difference in charge state. However, this
conclusion implicitly assumes that neutral methotrexate
and protonated methotrexate are bound in the same
conformation on the enzyme. This implicit assumption is
probably incorrect, since both folic acid (14, 15) and
dihydrofolic acid (16) appear to be bound in a different
conformation than protonated methotrexate on dihydro-
folate reductase. What is more likely to be correct is that
protonated methotrexate is bound in a conformation that
is less favorable for binding than folate or neutral meth-
otrexate except for the ionic interaction, but that the
strength of the ionic interaction overcomes the other
unfavorable aspects of its binding conformation. It has
long been believed, on the basis of quantum calculations
by Perault and Pullman (17) and Coffin and Pullman (18)
and by analysis of structure-activity relationships for
inhibitors by Hitchings and Burchall (3) and Baker (19),
that the increased basicity of N-i and the 2-amino group
in 2,4-diaminopteridines as compared with that of 2-
amino-4-oxopteridines is largely responsible for their sub-
stantially greater affinity for dihydrofolate reductase.
Laser raman studies by Saperstein et al. (20) showed
that methotrexate was protonated at N-i when bound to
dihydrofolate reductase. Our ab initio calculations also
support this view. It should be noted that there are many
assumptions and simplifications necessary to make these
calculations possible. It is probably true that our as-
sumptions and simplifications lead our calculations to
somewhat overstate the importance of the ionic bond,
relative to what a more elaborate calculation would in-
dicate. We believe that a more elaborate calculation
would confirm the essential features of our results, and
in particular would confirm the primacy of the ionic
interaction.
The difference between the UV absorbance of N-i-
protonated and neutral methotrexate above 300 nm
seems to match the change in the UV absorbance of
methotrexate upon binding to dihydrofolate reductase.
However, the change in UV absorbance upon enzyme
binding must be shifted 10 nm (6) to 40 nm (9) to shorter
wavelength to match the difference in UV absorbance
between N-i-protonated and neutral methotrexate. The
calculations given here provide an explanation for this
previously unexplained shift. In the ab initio calculations,
the net effect of introducing a proton is to increase the
HOMO versus LUMO separation for N-1-protonated
methotrexate as compared with that of neutral metho-
trexate. However, introducing the Asp 27 carboxylate has
a direct electrostatic effect on N-i and the 2-amino group,
decreasing the HOMO versus LUMO separation (&).
The HOMO of the protonated pteridine has a larger
coefficient on the 2-amino group than does the LUMO
(see Fig. 4), so its energy will be raised more by the
negatively charged carboxylate. This decreases the
HOMO versus LUMO separation (z#{128}).The carboxylate
oxygen atoms can also hydrogen-bond to N-i and the 2-
amino group and indirectly affect orbitals with large
densities on these atoms. The formamide and water
molecules have much smaller effects, since they are not
formally charged and do not interact as strongly. The
results of a plot of inverse of the wavelength of maximal
Uv absonbance (Amax) for the longest-wavelength absorb-
ance band ofneutral, N-1-protonated, and enzyme-bound
methotrexate against our calculated & between HOMO
and LUMO for neutral, N-1-protonated, and enzyme
model-bound 2,4-diamino-6-methylpteridine, respec-
tively, are given in Fig. 5. This correlation between
theoretical and experimental results for the UV data
gives us confidence that the assumptions and simplifica-
tions in our model are not too severe to prevent us from
drawing useful conclusions.
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